Danaher Q1: bioprocess strength

Danaher opened 2026 with uneven demand, but its bioprocessing business kept growing fast enough to support a higher profit outlook. (investors.danaher.com) The company reported first-quarter revenue of about $6.0 billion on April 21, with adjusted earnings of $2.06 a share, up 9.5% from a year earlier, while core revenue rose 0.5%. Net earnings were $1.0 billion, or $1.45 a share. (investors.danaher.com) Danaher said its Biotechnology segment delivered high-single-digit core growth, led by bioprocessing, while some research and applied markets remained softer. Management kept its full-year core revenue growth forecast at 3% to 6% and raised adjusted diluted net earnings guidance to $8.35 to $8.55 a share. (investors.danaher.com; finance.yahoo.com) Bioprocessing is the part of the drug industry that supplies the tools used to make biologic medicines, including filters, resins and single-use equipment for cell-culture production lines. Danaher’s update showed drug-manufacturing demand holding up better than demand for some lab instruments tied to academic and research spending. (finance.yahoo.com; investors.danaher.com) That split has shaped Danaher’s results for more than a year, as customers that make medicines have resumed ordering after earlier inventory cuts, while parts of life-science research have recovered more slowly. Chief Executive Rainer Blair said on the earnings call that bioprocessing remained strong and academic and government end markets were softer. (seekingalpha.com; investors.danaher.com) A day after earnings, Danaher priced a €3 billion senior-notes offering in four tranches due 2028, 2030, 2034 and 2038. The company said net proceeds of about €2.98 billion will help fund the cash portion and related costs of its Masimo acquisition. (investors.danaher.com) The notes included €500 million of floating-rate debt due 2028, €750 million of 3.250% notes due 2030, €750 million of 3.625% notes due 2034 and €1.0 billion of 4.000% notes due 2038. Danaher said the Masimo deal is expected to close on April 29, 2026, subject to customary conditions. (investors.danaher.com) That financing move adds a second track to the quarter: Danaher is balancing a still-choppy instrument market with a push to expand in higher-growth healthcare technology. The company’s first-quarter cash flow from operations was $1.3 billion, giving it another source of funding as it reshapes the portfolio. (investors.danaher.com; investors.danaher.com) For now, the quarter left Danaher with the same basic picture it had in April: steady overall growth, a stronger bioprocessing cycle, and weaker pockets in research tools. Management did not change its sales outlook, but it did lift its earnings target and move ahead with new debt to pay for its next acquisition. (investors.danaher.com; investors.danaher.com)